Not medical advice. Talk to your provider before using any peptide. Full disclaimer
GHK-Cu
Beginner tier: 1 mg, daily · community consensus
Also known as: GHK:Cu, copper tripeptide-1, copper peptide GHK
Three amino acids and a copper ion. That's the entire structure of the GHK-Cu peptide, a copper tripeptide the body already produces but loses roughly 60% of by age 60. Pickart and colleagues mapped its gene expression reach to at least 4,000 human genes [1], touching collagen, elastin, inflammation, and antioxidant pathways all at once. No human injectable RCT exists yet. That gap matters. But community experience across 100 to 200+ Reddit threads and biohacker forums consistently describes improved skin texture by week four, faster wound closure, and early hair regrowth at the temples. Available as both injectable and topical, GHK-Cu sits at the intersection of decades-old science and a still-growing user base.
What Is GHK-Cu?
At least 4,000 human genes. That's how many GHK-Cu raises or lowers in gene expression data analyzed by Pickart's group (PMID 26236730 (opens in a new tab))[1]. The GHK-Cu peptide (glycyl-L-histidyl-L-lysine copper(II), also written GHK:Cu or copper tripeptide-1) is a naturally occurring copper peptide found in human plasma, saliva, and urine. Plasma levels sit around 200 ng/mL at age 20 and drop to roughly 80 ng/mL by age 60.
The mechanism is broad. GHK-Cu upregulates collagen I, III, and V synthesis, boosts elastin and decorin production, and recruits immune and endothelial cells to damaged tissue. The copper ion itself is required for enzymatic processes in wound remodeling. In 2024, Bian and colleagues confirmed anti-fibrotic activity in silicosis mice and found lower plasma GHK in silicosis patients [2]. Its research now reaches past skin.
In practice, two routes dominate. Topical formulations (1 to 3% concentration) have cosmetic safety data going back decades; small clinical trials (n = 41 to 71) showed improved skin density and fine line reduction. Injectable use (0.5 to 2 mg/day subcutaneous) has no published dose-finding trial in humans but has one of the largest community evidence bases of any anti-aging peptide. Reports across r/Peptides, r/Biohackers, and practitioner networks describe improved skin firmness by weeks four to six; sentiment runs at 4.2 out of 5.
The honest limitation: all mechanistic data is in vitro or murine. Pro-angiogenic activity flagged by the NCI raises an unresolved theoretical oncology concern. GHK-Cu is classified as research-only and is not FDA-approved for any indication.
How GHK-Cu Works
GHK-Cu works at the gene expression level. Gene expression data analyzed by Pickart's group show it raises or lowers the activity of at least 4,000 human genes, suppressing some destructive pathways, when human cells are exposed to the peptide [1]. That's not a vague claim; the gene list is published and includes collagen I, III, and V, elastin, decorin (the scaffolding protein collagen needs to organize correctly), and antioxidant-related genes (Pickart and colleagues, Cosmetics 2015).
The copper(II) ion is load-bearing. Without it, the tripeptide GHK has limited biological activity. Copper activates lysyl oxidase, an enzyme required for collagen and elastin crosslinking. It also supports superoxide dismutase activity, which ties into the antioxidant gene data.
At the tissue level, GHK-Cu attracts both immune cells and endothelial cells to wound sites. This dual recruitment accelerates debris clearance and new blood vessel formation (angiogenesis). Pickart and Margolina described this in a 2008 review [4] as a "reset" toward a younger tissue repair program.
Recent work has extended these findings. Bian and colleagues showed GHK-Cu binds PRDX6 and eases lung fibrosis in silicosis mice (Redox Biology, 2024)[2]. A 2025 mouse study found it eased DSS-induced colitis, with SIRT1/STAT3 signaling implicated [5]. The peptide's reach keeps expanding, but the core mechanism remains the same: copper-dependent gene modulation that shifts tissue toward repair.
GHK-Cu Benefits
- GHK-Cu benefits center on collagen production, skin rejuvenation, and wound healing.
- Collagen I, III, and V synthesis all increase in fibroblast cultures exposed to GHK-Cu, confirmed by Maquart and colleagues in the original 1988 study [6]. That's the structural backbone of firmer, younger-looking skin.
- Community users consistently report visible fine line reduction and improved skin texture by weeks four to six. Over 100 Reddit threads in r/Peptides describe this as the single most reproducible outcome.
- Wound healing acceleration is both the oldest and best-supported benefit. Small cuts, post-surgical incisions, and acne scarring heal faster in both topical trials (n = 41 to 71) and community reports.
- Hair shedding decreases within four to six weeks for some users, with early regrowth at the temples or crown reported by week eight to sixteen. Published evidence is limited to follicle-level in vitro data, but user consistency is high.
- GHK-Cu's antioxidant effects come from lab and animal studies so far. Pickart's 2012 review [3] describes that antioxidant action and the peptide's high affinity for copper ions. A 2015 follow-up from the same group in Cosmetics proposes changes in antioxidant-related genes as the reason.
- Newer research points to anti-fibrotic potential beyond skin. In the 2024 silicosis study [2], GHK-Cu protected mouse lung tissue by binding PRDX6; patients with silicosis also had lower plasma GHK than controls.
GHK-Cu: Science vs Community Consensus
Preclinical evidence is strong for collagen stimulation, wound healing, and gene expression modulation (at least 4,000 human genes, up or down).
Read the evidence (key study, limitations)
Human clinical data is limited to small topical cosmetic trials. No human RCTs for injectable route exist. 2024–2025 mouse studies expanded applications to pulmonary protection [2] and colitis [5]. Core collagen and elastin mechanisms are well-validated in vitro and in animal models.
Pickart et al.: multiple landmark studies on GHK-Cu gene expression modulation (PMID 29986520, 26236730). Most recent: PMID 38879894 (Bian Y et al., Redox Biology, Sep 2024): GHK-Cu attenuates lung fibrosis in silicosis mice via PRDX6; includes plasma GHK data from 15 patients and 11 controls.
No human RCTs for injectable route. Topical clinical trials are small (n=41–71), non-blinded, or lack placebo arms. Nearly all mechanistic data is in vitro or murine. Skin penetration of topical GHK-Cu is limited due to hydrophilicity: liposomal delivery unmeasured (PMID 39795193). Pro-angiogenic activity raises theoretical oncology concern (NCI) that is unresolved in humans.
Highly positive community reception.
Read the reports (what users report 5, common issues 5)
Consistently rated one of the most tolerated anti-aging peptides. Skin texture improvement at 4–6 weeks is the most reproducible reported outcome. Hair regrowth and wound healing are common secondary uses. Topical overuse ("copper uglies") is the most-discussed adverse pattern.
- Improved skin texture and fine line reduction by weeks 4–6
- Accelerated wound, scar, and post-procedure healing
- Reduced hair shedding and early regrowth at temples/crown (8–16+ week timeline)
- Enhanced results after microneedling when applied immediately post-session (topical)
- General skin firmness and elasticity improvement
- "Copper uglies": paradoxical skin degradation from topical overuse or aggressive post-microneedling application (MMP-1 upregulation outpaces collagen synthesis)
- Injection site burning/stinging from copper ions: #1 injectable complaint
- mcg vs mg dosing confusion: common 1,000× calculation error in beginners
- Short reconstituted stability (~2–3 weeks) limits batch prep
- Zinc supplementation >50 mg/day competes with copper transport, reducing efficacy
Science and community agree on core benefits (collagen, wound healing, skin rejuvenation) and the topical route. Divergence exists on injectable dosing: community doses 1–3 mg/day SubQ without a published human dose-finding trial to support any specific number. Community primarily uses injectable for systemic anti-aging while published research focuses on topical and localized wound healing. Pro-angiogenic concern is under-discussed in community protocols.
GHK-Cu Dosage Guide
The blue-green color when you reconstitute is not contamination. It's the copper(II) ion doing exactly what it should. If your solution is colorless after proper reconstitution, that's actually the problem: copper may have dissociated, and potency drops with it.
Reconstitution math for common vial sizes: a 5 mg vial plus 2 mL bacteriostatic water gives you 2,500 mcg/mL. A 1 mg dose (1,000 mcg) equals 0.4 mL, which is 40 units on a U-100 insulin syringe. For the 50 mg vial plus 5 mL bacteriostatic water, you get 10,000 mcg/mL; a 1 mg dose is just 0.1 mL or 10 units.
Store reconstituted vials in a dark refrigerator. Copper ions are photosensitive. Expect two to three weeks of usable shelf life.
Start at 500 mcg/day for injectable and titrate up over two weeks. Evening injection is the community standard. Rotate abdominal sites and don't hit the same spot more than once per week; lipodystrophy from poor rotation is a real and visible consequence.
Cycling Protocol
Cycle 4-8 weeks for injectable use. Topical application can be used continuously without cycling.
Injectable GHK-Cu cycling serves two purposes: (1) copper accumulation management: daily parenteral copper peptide adds measurable systemic copper load, and continuous long-term use without monitoring creates theoretical accumulation risk; (2) pathway sensitivity: GHK-Cu raises or lowers the activity of at least 4,000 human genes and activates multiple repair pathways; periodic off cycles are speculated to maintain sensitivity, though no human data confirms desensitization occurs. Topical GHK-Cu at ≤3% does not require cycling due to minimal systemic copper absorption.
- Diminishing skin improvement response after 6–8 weeks of continuous use
- Injection site burning or metallic taste worsening rather than improving over time
- Serum copper trending toward high-normal (>120 mcg/dL) on lab monitoring
- Nausea or GI discomfort developing mid-cycle at previously tolerated doses
Or use the universal Peptide Calculator for any peptide.
GHK-Cu Protocols by Goal
Expected: Improved skin texture and hydration by weeks 2–4. Visible fine line reduction and improved firmness by weeks 6–8. Collagen remodeling continues through week 12.
Monitor: Discontinue if paradoxical skin worsening occurs (copper uglies: accelerated sagging or wrinkling). This indicates MMP-1 overactivation; reduce concentration and frequency.
How to Use GHK-Cu
- 1Step 1
Gather supplies: GHK-Cu lyophilized vial, bacteriostatic water, alcohol swabs, U-100 insulin syringe (29 to 31 gauge, 0.5 inch needle).
- 2Step 2
Clean both vial stoppers with alcohol swabs and let dry.
- 3Draw your bacteriostatic water volume
For a 5 mg vial, use 2 mL. For a 50 mg vial, use 5 mL.
- 4Inject the water slowly against the vial wall
Do not spray directly onto the powder. Swirl gently until dissolved. The solution will turn blue-green; this is normal and expected.
- 5Calculate your dose
At 5 mg in 2 mL: 1 mg (1,000 mcg) = 40 units on the syringe. At 50 mg in 5 mL: 1 mg = 10 units on the syringe.
- 6Step 6
Draw your dose, removing air bubbles by tapping the syringe barrel.
- 7Step 7
Pinch a fold of abdominal skin (or near your target area for localized effects). Insert needle at a 45-degree angle. Inject slowly.
- 8Step 8
Withdraw the needle, apply light pressure with an alcohol swab. If you experience copper sting, hold a cold compress for 60 seconds.
- 9Rotate injection sites
Map at least six to eight abdominal locations and cycle through them. No site more than once per week.
- 10Step 10
Store the reconstituted vial upright in a dark refrigerator (2 to 8 degrees Celsius). Use within two to three weeks.
Alternative Routes
Standard systemic: 0.5–2 mg/day. Peri-target SubQ (near scalp for hair, face perimeter for skin) uses same dose with smaller volume and finer needle (31G).
Estimated SC bioavailability ~90–95%. Rapid plasma clearance (~1 hour half-life) but cellular effects persist. Evening injection preferred. No more than 1 injection per site per week to prevent lipodystrophy.
1–3% concentration standard; up to 5% in clinical formulations. Skin penetration is limited by hydrophilicity: microneedling or liposomal encapsulation significantly enhances delivery.
No meaningful systemic copper load at standard concentrations. "Copper uglies" risk at high concentrations or aggressive post-microneedling use. MMP-1 upregulation may outpace collagen synthesis. Can be used continuously (no cycling required) at ≤3% concentration.
Apply 0.5–2% GHK-Cu serum immediately post-microneedling (0.5–1 mm needle depth). Wait 48–72 hours minimum in beginners to assess copper irritation response on disrupted skin barrier.
Do not exceed 2% concentration immediately post-microneedling. Disrupted skin barrier allows excess copper penetration and amplifies MMP-1 upregulation risk. Space microneedling sessions 3–4 weeks apart.
GHK-Cu Stacking Protocols
Works With
Core GLOW blend: GHK-Cu provides ECM remodeling and collagen synthesis; BPC-157 provides vascular support and cytoprotection. Complementary mechanisms for skin, wound, and tissue healing.
GHK-Cu 1 mg/day SubQ + BPC-157 250 mcg/day SubQ, same cycle length
TB-500 handles cytoskeletal reorganization and cell migration; GHK-Cu handles ECM collagen remodeling. Complementary anti-fibrotic and repair mechanisms.
GHK-Cu 1 mg/day SubQ + TB-500 2 mg, 2–3x/week SubQ
Longevity stack: Epithalon works via telomerase activation and epigenetic mechanisms; GHK-Cu via gene expression and collagen. Additive anti-aging mechanisms targeting different pathways.
GHK-Cu 500 mcg–1 mg/day + Epithalon 10 mg/day for 10-day Epithalon pulse cycles
Mitochondrial and anti-aging pairing. NAD+ supports cellular energy and sirtuin pathway; GHK-Cu modulates repair gene expression. Combined in longevity protocols targeting multiple aging mechanisms.
GHK-Cu 500 mcg–1 mg/day SubQ + NAD+ 100–500 mg IV or SubQ
Avoid
Competitive inhibition at copper transport sites. High-dose zinc displaces copper in transporter binding, reducing GHK-Cu cellular uptake and bioavailability.
Directly chelate the copper ion in GHK-Cu, reducing bioavailability by 60–80% and unpredictably altering free copper levels. Critical drug interaction.
Do not combineHigh-concentration ascorbic acid chelates copper ions, reducing topical GHK-Cu activity. Separate topical application by at least 2 hours.
How much does GHK-Cu cost?
Typical price
$0.452 to $0.70 per mg
Middle half of 114 US prices for 100 mg vials · read Oct 31
Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.
Pricing updated 2026-04-09
GHK-Cu Side Effects
The most serious concern with GHK-Cu is its pro-angiogenic activity. The NCI flagged this years ago: a peptide that promotes new blood vessel formation could, in theory, support tumor vascularization. No human case has confirmed this, but no study has ruled it out either. Anyone with an active malignancy should not use GHK-Cu without oncologist clearance.
Copper toxicity is the second concern worth taking seriously. Continuous long-term use without lab monitoring creates an accumulation risk. Wilson's disease, hemochromatosis, and any copper metabolism disorder are absolute contraindications. Symptoms of copper excess include nausea, metallic taste, and jaundice; if these appear, stop immediately and get serum copper checked.
Published side effects in topical trials are mild. Skin irritation, redness, and occasional contact sensitivity at higher concentrations. The more interesting adverse pattern comes from the community: "copper uglies." This is paradoxical skin worsening (sagging, accelerated wrinkling) caused by MMP-1 matrix metalloproteinase upregulation outpacing collagen synthesis. It happens most often with topical overuse or aggressive post-microneedling application. The fix is simple: drop to 1% concentration and wait 48 to 72 hours after microneedling before applying.
Injectable side effects are dominated by injection site reactions. Burning and stinging from the copper ions is the number one complaint in community threads. Diluting with more bacteriostatic water, using a 31-gauge needle, and applying a cold compress for 60 seconds post-injection helps. Site rotation matters; no location should get more than one injection per week. Poor rotation leads to lipodystrophy (localized fat atrophy), which is harder to reverse than it sounds.
At doses above 1.5 mg/day, some users report nausea and metallic taste. These are dose-dependent and resolve with reduction.
Reconstituted stability is limited to two to three weeks refrigerated. Potency drops 15 to 30% by week four according to community tracking. The mcg versus mg calculation error is a real hazard for beginners; GHK-Cu vials are labeled in mg but doses are discussed in mcg. 1 mg equals 1,000 mcg. Getting this wrong by a factor of 1,000 is not theoretical; it's the most common beginner mistake in the community.
Contraindications: Wilson's disease or copper metabolism disorders. Known hypersensitivity to GHK-Cu or copper compounds. Pregnancy or breastfeeding (no safety data). Hemochromatosis. Active malignancy without oncologist clearance. Severe kidney or liver dysfunction.
Drug interactions: copper-chelating agents (penicillamine, trientine) reduce bioavailability by 60 to 80%. Zinc above 50 mg/day competes at copper transport sites. High-concentration topical vitamin C (15%+) chelates copper; separate application by two or more hours. Immunosuppressants may interact with the healing response; consult a prescriber.
Common Issues & Solutions
Blue-green solution is NORMAL: intact copper(II)-peptide complex. A colorless solution may indicate copper dissociation and reduced potency. Do not discard blue-green vials.
Injection site burning/copper sting: reduce dose by 50% and dilute with more BAC water; use 31G needle; apply cold compress 60 seconds post-injection. Persistent site reactions indicate inadequate rotation (no site should receive >1 injection/week).
mcg/mg calculation error: GHK-Cu research vials are labeled in mg (5 mg, 50 mg); doses are discussed in mcg. 1 mg = 1,000 mcg. At 5mg vial + 2mL BAC water = 2,500 mcg/mL; a 1 mg dose = 0.4 mL = 40 IU on U100 syringe. Verify concentration calculation before every new vial.
"Copper uglies" from topical overuse: paradoxical skin worsening (sagging, wrinkling) caused by MMP-1 upregulation outpacing collagen synthesis at high concentrations or immediately post-microneedling. Fix: reduce to 1% concentration, wait 48–72 hours after microneedling before applying, space to once daily.
No response by week 6 (injectable): confirm proper SubQ depth (not intradermal: intradermal causes welts and poor absorption), verify reconstituted concentration, and rule out zinc supplement competition (>50 mg/day zinc blocks copper transport).
Ask AI about this page
Ask AI for a second opinion on GHK-Cu dosing and side effects
Contraindications
- Wilson's disease or other copper metabolism disorders
- Known hypersensitivity to GHK-Cu or copper compounds
- Pregnancy or breastfeeding (insufficient safety data)
- Hemochromatosis or copper overload conditions
- Active malignancy without oncologist clearance (GHK-Cu modulates growth-related genes)
- Severe kidney or liver dysfunction (may impair peptide clearance)
Drug Interactions
- Copper-chelating agents (penicillamine, trientine): may reduce GHK-Cu bioavailability by 60-80% and alter free copper levels
- Zinc supplements above 50mg/day: competitive inhibition at copper transport sites can reduce cellular uptake
- Topical vitamin C serums (high-concentration ascorbic acid): may chelate copper and reduce activity; separate application by 2+ hours
- Immunosuppressants: GHK-Cu may amplify healing responses; consult prescriber before combining
- Directly chelate the copper ion in GHK-Cu, reducing bioavailability by 60–80% and unpredictably altering free copper levels. Critical drug interaction.
Product Quality
GHK-Cu is a simple tripeptide (Gly-His-Lys + Cu²⁺) that is relatively straightforward to synthesize, reducing complex adulterant risk. However, injectable research-grade GHK-Cu is not produced under sterile conditions (not USP 797 compliant), creating endotoxin and sterility risks. The compounding pharmacy channel splits by route: injectable GHK-Cu is listed as withdrawn from Category 2 (FDA page current as of April 22, 2026) with no compounding access today (no FDA rule has added it to the 503A bulks list), while non-injectable GHK-Cu is back on FDA's 503A Category 1 list as of May 14, 2026. The mcg/mg dosing confusion and topical "copper uglies" risk are behavioral quality risks.
- A useful COA shows HPLC purity ≥98% and mass spectrometry confirmation
- Research-grade products typically lack endotoxin or sterility testing: for injectable use, this represents an unmitigated risk vs. compounding pharmacy
- Use bacteriostatic water (not plain sterile water) for reconstitution to extend shelf life to 2–3 weeks refrigerated
- Protect reconstituted solution from light: copper ions are photosensitive; store in a dark refrigerator
- Blue-green color confirms intact Cu²⁺ coordination; colorless solution after proper preparation warrants quality verification
- For compounded injectable: confirm USP 797 compliance, PCAB accreditation, and endotoxin testing at the compounding pharmacy
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Serum copper | Baseline; recheck at 8 weeks if running extended or high-dose injectable cycles (>1.5 mg/day) | 70–140 mcg/dL (adult normal) |
| Ceruloplasmin | Baseline if Wilson's disease or copper metabolism disorder is suspected | 15–60 mg/dL |
| Liver function panel (ALT, AST, bilirubin) | Baseline for advanced protocols; 8-week check if running high-dose or extended cycles | ALT <56 U/L, AST <40 U/L (lab-specific ranges apply) |
| Serum zinc | Baseline if taking zinc supplements at >25 mg/day | 60–120 mcg/dL |
Injectable GHK-Cu adds systemic copper load; monitoring confirms copper remains within normal range and accumulation has not occurred
Ceruloplasmin is the primary copper transport protein; low ceruloplasmin indicates impaired copper handling and is a contraindication to GHK-Cu use
Copper accumulation is hepatotoxic at excess levels; liver enzymes provide early warning. Also relevant given GHK-Cu modulation of hepatic gene expression.
High-dose zinc (>50 mg/day) competitively inhibits copper transport and reduces GHK-Cu efficacy; adjust zinc supplementation if low response is observed
GHK-Cu Before and After
Initial cellular signaling begins. Gene expression shifts toward repair pathways. Skin may feel slightly more hydrated. No visible changes yet.
Early improvements in skin texture and tone. Minor wounds and blemishes heal faster. Collagen synthesis is ramping up at the cellular level.
Noticeable reduction in fine lines. Skin appears firmer and more elastic. Hair shedding may decrease in those using for hair regrowth.
Peak results for an 8-week injectable cycle. Visible improvement in wrinkles, skin firmness, and wound healing. Some users report early hair regrowth at the temples or crown.
Benefits persist due to sustained collagen remodeling. Topical GHK-Cu can be continued during the off period to maintain skin-level results.
What to Expect
Weeks 1 to 2 (Cellular Signaling Onset): Gene expression changes begin within hours. Repair genes, collagen I/III/V, and elastin pathways activate at the cellular level. Nothing visible yet. Most users notice their skin feels slightly more hydrated, and small injection-site nicks heal faster than expected. The blue-green solution color surprises first-timers, but it confirms the copper-peptide complex is intact. Expect injection site burning from the copper ions; mild redness is common. Nausea at doses above 1.5 mg is rare.
Weeks 2 to 4 (Early Tissue Response): Collagen synthesis is ramping up. Elastin deposition is underway. Hair follicle miniaturization signals may start to reverse. Community users describe an improved skin "glow" and noticeably faster healing of minor wounds and blemishes. Topical users report more even skin tone. Hair shedding may slow down. Injection site reactions typically normalize by this point if you're rotating properly. Some users report occasional metallic taste at higher doses.
Weeks 4 to 6 (Visible Skin Changes): This is the most consistent benefit window in community reports. Skin feels firmer. Fine lines are visibly reduced. Texture is smoother. Some users see early hair regrowth at the temples or crown. Topical trial data supports measurable increases in skin density and elasticity during this timeframe.
Weeks 6 to 8 (Peak Cycle Results): Maximum collagen remodeling within the cycle. Anti-fibrotic effects peak. Gene expression changes are fully established. Wrinkle reduction and skin firmness hit their best. Stacked users running the GLOW blend (BPC-157 and TB-500) report more dramatic results. Watch for lipodystrophy if you've been lazy with site rotation.
Post-cycle, 4-week off (Consolidation): Collagen remodeling is slow by nature. Benefits persist four to eight weeks after stopping because the ECM changes are structural, not pharmacological. Most users maintain visible improvements through the entire off period. Topical GHK-Cu at 2% or lower is commonly continued during the break for skin maintenance.
Detailed Timeline: Science vs Community
Gene expression modulation begins within hours of administration. Upregulation of repair genes, collagen I/III/V, and elastin synthesis initiated at the cellular level. No macroscopic changes expected.
Skin feels slightly more hydrated. Some users notice injection site heals faster than usual. No visible skin changes yet. Blue-green solution color often surprises first-time users (it is normal).
Collagen synthesis ramping up. Elastin deposition beginning. Wound healing acceleration measurable histologically. Hair follicle miniaturization signals may begin to reverse.
Improved skin texture and "glow." Minor wounds and blemishes heal noticeably faster. Topical users report better skin tone evenness. Hair shedding may decrease.
Measurable increases in skin density and elasticity based on topical trial data. Fine line reduction becomes histologically measurable.
Most consistent benefit window: skin firmer, fine lines reduced, texture smoother. First reports of early hair regrowth appearing at temples or crown.
Maximum collagen remodeling within the cycle. Anti-fibrotic effects peak. Gene expression changes fully established.
Visible wrinkle reduction and skin firmness peak. Wound/scar remodeling visibly improved. Stacked users (GLOW blend with BPC-157/TB-500) report more dramatic outcomes.
Collagen remodeling is slow: benefits persist 4–8 weeks post-cycle due to sustained ECM changes. Gene expression returns toward baseline gradually.
Most users maintain visible improvements through the off period. Topical GHK-Cu commonly continued during off cycle for skin maintenance at ≤2% concentration.
Pharmacokinetics
Source: Estimated from plasma degradation studies; rapid enzymatic cleavage by peptidases gives a ~30-60 min range
Pharmacokinetics: Active Dose Over Time
t½ = ~1 hourDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is GHK-Cu Legal?
GHK-Cu is classified as a research chemical in the United States. It has no FDA approval for any indication. Sale is permitted for in vitro research purposes only; "not for human consumption" labeling is standard on research-grade products.
FDA splits GHK-Cu by route. Injectable GHK-Cu was on the FDA Category 2 list until its nominators withdrew it; FDA's Category 2 page (current as of April 22, 2026) lists it as withdrawn, and no FDA rule has added injectable GHK-Cu to the 503A bulks list, so compounding pharmacies cannot use it for injection today. Non-injectable GHK-Cu is back on FDA's 503A Category 1 list (substances under evaluation) as of May 14, 2026, after one nominator kept that part of its nomination. FDA says it intends to consult PCAC on GHK-Cu before the end of February 2027.
GHK-Cu is not on the WADA prohibited substances list as of 2026.
Topical GHK-Cu products are sold as cosmetic ingredients (copper tripeptide-1 per INCI) and face fewer regulatory restrictions. They do not require a prescription.
Injectable research-grade GHK-Cu is lyophilized powder without sterility or endotoxin testing.
This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before using any peptide product.
Evidence grade: Small human studies only (Peptide Evidence Gap, October 2026)
Who Should Consider GHK-Cu
- Adults seeking to reduce visible signs of skin aging (fine lines, wrinkles, loss of elasticity)
- Individuals recovering from wounds, surgical incisions, or skin injuries
- Men and women experiencing age-related hair thinning
- Adults over 40 with declining endogenous GHK levels
- Patients looking for collagen and elastin support without growth hormone use
Related Peptides
What Changed for GHK-Cu
- Safety
Corrected Oct 20, 2026: GHK-Cu side effects drop an unsourced line that injected copper stays below toxic levels; the copper limit is for intake, per IOM 2001.
Before: At typical community doses (1 to 2 mg/day subcutaneous), the copper load stays well below toxic thresholds. After: Line dropped: no upper limit is set for injected copper (the IOM limit covers intake from food, water and supplements); the accumulation caution and copper checks stay.
What this does not mean: No new copper risk was found, and the dose tiers are unchanged. The IOM set its 10 mg a day upper limit for copper from food, water and supplements. It gives no figure for injected copper.
Source: Institute of Medicine 2001, Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc, chapter 7 (Copper): adult upper limit 10,000 mcg/day, set on liver damage (PMID 25057538) (opens in a new tab) · Archived snapshot (opens in a new tab)
- Dosing
Corrected Oct 19, 2026: GHK-Cu's moderate tier is 2 mg daily, not 2.5 mg, the top of its 1 to 2 mg community range; no trial set an injected dose, per PubMed.
Before: Beginner 1,000, moderate 2,500, aggressive 3,000 mcg daily After: Beginner 1,000, moderate 2,000, aggressive 3,000 mcg daily
What this does not mean: No new study, and no dose is newly supported: the tiers are community figures. GHK-Cu's human trials are topical, such as Miller 2006; no human study has tested it alone as an injection. Beginner 1 mg and aggressive 3 mg are unchanged.
Source: Arch Facial Plast Surg 2006, Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin (Miller et al.), a randomized trial of topical GHK-Cu (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Safety
Corrected Oct 17, 2026: GHK-Cu's safety grade is now B, not A; FDA says human data on injectable GHK-Cu are limited, per its Category 2 page.
Before: A After: B
What this does not mean: No new safety finding, and the doses did not change. Grade A needs extensive human data or long-established use. The human data for GHK-Cu are small topical skin studies; no human study has tested it as an injection.
Source: FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 page, captured Oct 6, 2026) (opens in a new tab) · Saved copy
- Regulatory
FDA put non-injectable GHK-Cu back in 503A category 1 after a nominator kept that route, per the FDA 503A categories list updated May 14, 2026.
What this does not mean: Category 1 means under evaluation. It is not the 503A bulks list, and injectable GHK-Cu stays out of every category.
Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated May 14, 2026) (opens in a new tab) · Saved copy
- Regulatory
FDA took non-injectable GHK-Cu off 503A category 1 on Apr 22, 2026 after its nominations were withdrawn, per the FDA 503A categories list.
What this does not mean: It concerns 503A compounding nominations only. It is not a new FDA safety finding about GHK-Cu.
Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated May 14, 2026) (opens in a new tab) · Saved copy
- RegulatoryEffective
Nominators withdrew 12 peptides (GHK-Cu for injectable routes only) from 503A category 2, announced Apr 15, 2026, per the FDA 503A categories list.
What this does not mean: Leaving category 2 does not put a peptide on the 503A bulks list or make it eligible for compounding. That takes FDA rulemaking, and none has been proposed (Federal Register search, Oct 6, 2026).
Also covers: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epithalon, LL-37, Dihexa, PEG-MGF, Melanotan II
Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated April 22, 2026; the April 15, 2026 notice version is archived beside it) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
Dates to watch
- Committee review
FDA intends to consult its compounding advisory committee on adding these peptides to the 503A bulks list, per FDA.
What this does not mean: No meeting date is set yet. A committee vote is advice to FDA, not a rule; the 503A bulks list changes only through notice-and-comment rulemaking.
Also covers: LL-37, Dihexa, Melanotan II, PEG-MGF
Peptide Schedule Research TeamReviewed Aug 7, 202616 Citations
References
- [1]Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]The glycyl-L-histidyl-L-lysine-Cu2+ tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6 (Redox Biology 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health (Pickart et al., Oxid Med Cell Longev 2012) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]The human tri-peptide GHK and tissue remodeling (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms (Front Pharmacol 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex GHK-Cu2+ (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration (opens in a new tab)PubMed 26236730PubMed
- GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes (Pickart et al., Cosmetics 2015) (opens in a new tab)Review
- Are we ready to measure skin permeation of modern antiaging GHK-Cu tripeptide encapsulated in liposomes? (Ogorek et al., Molecules 2025) (opens in a new tab)PubMed 39795193PubMed
- Injectable hydroxyapatite microsphere filler with GHK-Cu for sustained dermal collagen remodeling (Colloids Surf B Biointerfaces 2025) (opens in a new tab)PubMed 40716276PubMed
- Copper Complexes with Glycyl-L-histidyl-L-lysine-Hyaluronan Conjugates: molecular assembly and bioactivity (Bioconjug Chem 2025) (opens in a new tab)PubMed 40123442PubMed
- Food-Derived Tripeptide-Copper Self-Healing Hydrogel for Infected Wound Healing (Biomater Res 2025) (opens in a new tab)PubMed 39902373PubMed
- Palmitoyl copper peptide enhances melanin production in melanocytes (Biochem Biophys Res Commun 2025) (opens in a new tab)PubMed 39632290PubMed
- GHK prevents copper/zinc-induced protein aggregation: implications for neurodegeneration (Metallomics 2024) (opens in a new tab)PubMed 38599632PubMed
- Rigid-flexible nanocarriers with GHK-Cu for antioxidant and anti-inflammatory skin applications (Colloids Surf B Biointerfaces 2024) (opens in a new tab)PubMed 38394858PubMed
- Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective (BioImpacts 2024) (opens in a new tab)PubMed 39963574PubMed
Related Resources
Related Tools
Further Reading
Storage & Stability
Frequently Asked Questions
How popular is GHK-Cu?
Popular. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 100–200+. Community mentions on Reddit: ~100–200+ threads (r/Peptides, r/Biohackers). Open r/Peptides (opens in a new tab).
162 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Moderate search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.